- Home
- ELOX vs GSIW Comparison
ELOX vs GSIW Comparison
Compare ELOX & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ELOX | GSIW |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | Hong Kong |
| Employees | 7 | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.0M | 42.6M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | ELOX | GSIW |
|---|---|---|
| Price | $17.43 | $21.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 58.2K | 10.1K |
| Earning Date | N/A | 08-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.00 | $0.05 |
| 52 Week High | $15.00 | $38.55 |
Technical Indicators
Market Signals| Indicator | ELOX | GSIW |
|---|---|---|
| Relative Strength Index (RSI) | 56.47 | 37.77 |
| Support Level | $10.74 | $0.11 |
| Resistance Level | $14.37 | $33.00 |
| Average True Range (ATR) | 1.54 | 1.46 |
| MACD | 0.24 | -0.48 |
| Stochastic Oscillator | 85.22 | 0.00 |
Price Performance
Historical ComparisonAbout ELOX Eloxx Pharmaceuticals Inc. Common Stock
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.